about
Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data.Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantationChanges in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity.Pullulan: a new cytoadhesive for cell-mediated cartilage repair.Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications.vIL-10-overexpressing human MSCs modulate naïve and activated T lymphocytes following induction of collagenase-induced osteoarthritis.Donor bone marrow-derived dendritic cells prolong corneal allograft survival and promote an intragraft immunoregulatory milieu.Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation.Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.Targeting colon cancer cell NF-κB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis.Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.Regulation of NF-kappaB responses by epigenetic suppression of IkappaBalpha expression in HCT116 intestinal epithelial cells.Fas ligand promotes tumor immune evasion of colon cancer in vivo.Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response.Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways.Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment.Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat.Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic 'activated' state that enhances prostate cancer cell migration.Extracellular vesicles as modulators of wound healing.The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation.Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal TransplantationInterspecies Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the RatStromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon CancerCyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
P50
Q25256768-B9970151-1B3B-4410-868F-EEBA0C5D94C9Q27324639-035586E9-EEB2-44CB-BAA1-9A034122743BQ34803754-6750A780-5CAD-471D-BD54-FBBCCCDF3AE5Q35067698-C24621B0-3DB8-4A96-BB66-FDE9EA03D56EQ35552862-8870328A-7D31-4F0C-9C6D-903AA3DC0466Q35594874-B7AD1A75-106D-4E4C-A93D-7D43F59A35E8Q36911289-5B2AE568-88DC-4ACA-8837-B9EF24FE2D6BQ37316849-D723A977-A347-4947-B004-6523067D158EQ37620828-A8EB8F62-A6FE-4FA0-B6F7-A88271F7B257Q37645095-FFEC2E94-9F19-44AA-85D3-83946BF76C59Q38064659-EA745DC9-1133-4AF9-B294-53E5B7CD3E4DQ38866710-4000F7E4-2E49-42D8-91F0-1387F680457DQ39007389-47AB522E-F33F-4F0E-A353-83F7117D455DQ39061029-C9CC0026-D326-4645-A116-DEBDF3C11533Q39716995-6EFC50C0-12FA-4C3A-9C19-3474E1BD459AQ40328380-F5D86A84-F41F-4175-9FE7-12531075343BQ40355339-95EA9859-3F3E-4E3F-AF2D-E0C2887EFF8AQ40401847-7E333251-0A42-4FBC-B3B8-2B18E5DEB2A9Q45412843-BD27F7AC-6003-460B-B56E-6D1F0B99BA89Q47105736-EB6D953A-418E-4228-88B8-83DBD476FE1EQ47147635-F090A75D-684B-4D16-BDC3-381AD0491B9EQ47325556-FFA6BE83-0B28-4BD4-BCE7-08A413EFC337Q48211721-22AD9709-03C6-4364-9B84-EF437F963BDDQ48368979-3716B90E-4CFA-4D1B-87E3-D043581A8C8BQ50169468-6C9A5A0E-0862-436C-9914-41A962AA1B5CQ53327728-C518636E-30BD-4604-9F20-C37D8FF25AC5Q54188853-B3540FD0-386E-41A9-8194-A76AD1C26552Q59791597-CFA68F7C-0E4F-46D4-ABDF-B64EC1A274DAQ88565461-EBB28CB8-B697-4FC2-BC6F-B1DD0B52FD73Q91517902-64B97876-142E-4F05-81F5-20696E62A042Q92760001-39C85AA5-39C4-410F-931D-4DF242F01D8F
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5831-6783
@en
name
Aideen E Ryan
@ast
Aideen E Ryan
@en
Aideen E Ryan
@es
Aideen E Ryan
@nl
type
label
Aideen E Ryan
@ast
Aideen E Ryan
@en
Aideen E Ryan
@es
Aideen E Ryan
@nl
prefLabel
Aideen E Ryan
@ast
Aideen E Ryan
@en
Aideen E Ryan
@es
Aideen E Ryan
@nl
P106
P108
P1153
8861835800
P31
P496
0000-0002-5831-6783